Related Experiment Video
Updated: Dec 26, 2025
08:18
Focus Formation: A Cell-based Assay to Determine the Oncogenic Potential of a Gene
Published on: December 31, 2014
28.6K
MYC Dysregulates Mitosis, Revealing Cancer Vulnerabilities
Julia Rohrberg1, Daniel Van de Mark1, Meelad Amouzgar1
1Department of Cell & Tissue Biology, University of California, San Francisco, San Francisco, CA, USA.
Cell Reports
|March 12, 2020
Summary
MYC oncogene overexpression causes cancer aneuploidy by disrupting cell division (mitosis). Reducing MYC levels or targeting TPX2 can reverse these defects, offering potential cancer therapy strategies.
Area of Science:
- Oncology
- Cell Biology
- Genetics
Background:
- Tumors overexpressing the MYC oncogene often exhibit aneuploidy, a characteristic linked to aggressive cancers and tumor evolution.
- The precise mechanisms by which MYC drives aneuploidy remain incompletely understood.
Purpose of the Study:
- To elucidate how MYC overexpression leads to aneuploidy and chromosomal instability (CIN).
- To investigate the role of TPX2 in MYC-driven aneuploidy and its therapeutic potential.
Main Methods:
- Analyzing the impact of MYC overexpression on mitotic spindle assembly and microtubule organization.
- Assessing the effects of MYC and TPX2 modulation on mitotic progression, cell death, and tumor growth.
- Investigating gene expression changes related to mitosis in MYC-high cells.
Main Results:
- MYC overexpression induces mitotic spindle defects and CIN by affecting microtubule nucleation and organization.
- Decreasing MYC expression reverses these mitotic defects, even in established tumor cells.
- TPX2 facilitates spindle assembly in MYC-high cells; its depletion halts mitosis and prevents tumor growth.
- Elevating TPX2 expression mitigates mitotic defects in MYC-high cells.
Conclusions:
- MYC is a key regulator of mitosis and chromosomal instability.
- Targeting MYC or TPX2 presents a potential strategy to combat aneuploidy and tumor evolution in MYC-driven cancers.
- MYC and TPX2 expression levels may serve as biomarkers for patient stratification in anti-mitotic therapy.
Related Concept Videos
01:06Induced Pluripotent Stem Cells
5.2K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
5.2K
02:23Abnormal Proliferation
5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
02:38Mitogens and the Cell Cycle
7.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
03:03mTOR Signaling and Cancer Progression
4.5K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.5K
02:15M-Cdk Drives Transition Into Mitosis
6.2K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
02:21Cancers Originate from Somatic Mutations in a Single Cell
14.4K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.4K